Adamis Pharmaceuticals logo
Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19
June 11, 2021 07:30 ET | Adamis Pharmaceuticals Corporation
SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that clinical trial start-up activities are underway for examining the effects of...
ARC logo.png
Antiviral Drugs Market Value Projected To Reach US$ 74.7 Billion By 2027: Acumen Research And Consulting
April 01, 2021 11:16 ET | Acumen Research and Consulting
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Antiviral Drugs Market– Global Industry Analysis, Market Size, Opportunities and...
white-CSS logo.jpg
Cambridge Security Seals Broadens Offering to Airlines In Anticipation of Global Travel Rebound
February 02, 2021 10:20 ET | Cambridge Security Seals
Pomona, New York, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Cambridge Security Seals (CSS), a global leader and innovator in tamper-evident seals and security solutions, announced today that it had expanded...
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19
December 15, 2020 08:30 ET | ARCA biopharma, Inc.
rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccinesrNAPc2 is the only novel compound being developed for COVID-19...
AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation
November 23, 2020 08:30 ET | ARCA biopharma, Inc.
Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or notAB201 is the only novel compound being developed for COVID Associated...
ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update
November 02, 2020 08:30 ET | ARCA biopharma, Inc.
Initiation of Phase 2b clinical trial evaluating AB201 as a potential treatment for COVID19 anticipated in fourth quarterTopline data from trial anticipated Q2 2021 WESTMINSTER, Colo., Nov. 02,...
RedHill Biopharma Announces Partnerships to Expand Manufacturing for COVID-19 Therapeutic Candidate Opaganib
October 13, 2020 10:30 ET | RedHill Biopharma Ltd.
        Collaborations with European and Canadian suppliers for large-scale ramp-up of opaganib manufacturing further strengthens manufacturing capabilities and capacity, in preparation for potential...
RedHill Biopharma’s Opaganib COVID-19 Study Passes Second Independent Committee Review
October 07, 2020 10:00 ET | RedHill Biopharma Ltd.
Second pre-scheduled independent Safety Monitoring Committee (SMC) review unanimously recommends continuation without change of the U.S. Phase 2 study with opaganib in COVID-19 --The U.S. Phase 2...
Logo - RBT.jpg
Renibus Therapeutics’ COVID-19 Treatment, RBT-9, Shows Antiviral Activity Against SARS-CoV-2 In Vitro
October 07, 2020 09:00 ET | Rénibus Therapeutics Inc.
DALLAS, Texas, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that its investigational treatment for COVID-19, RBT-9, has...
ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19
October 07, 2020 08:30 ET | ARCA biopharma, Inc.
Initiation of Phase 2b clinical trial anticipated in Q4 2020Trial to enroll approximately 100 patients hospitalized with COVID-19Topline data anticipated Q2 2021 WESTMINSTER, Colo., Oct. 07, 2020 ...